Chugai Pharma to transfer Japanese marketing authorization of anti-cancer agent, Xeloda tablets 300 to Cheplapharm

Chugai Pharmaceutical Co., Ltd. and Cheplapharm K.K. announced that Chugai will transfer the business in Japan concerning the anti-cancer agent “Xeloda tablets 300” to Cheplapharm. Chugai in-licensed Xeloda from Roche and is the marketing authorization holder in Japan.

Chugai has been marketing Xeloda and providing information in Japan since 2003. In consideration of the maturity of the product lifecycle, Chugai, Roche, Cheplapharm group revisited the marketing of Xeloda in Japan and concluded that Cheplapharm group should solely market Xeloda after transferring assets related to Xeloda that are owned by Roche and Chugai, including the marketing authorization and intellectual property rights (patents and trademarks, etc.), to Cheplapharm group.

Cheplapharm and Chugai are proceeding with the necessary administrative and legal procedures for the completion of the transaction. The transfer of the marketing authorization is scheduled to take place on February 1, 2024, and the sales transfer is scheduled to take place on April 1, 2024. Cheplapharm will be solely responsible for the marketing and information provision activities for Xeloda in Japan thereafter.

Cheplapharm and Chugai will cooperate to ensure a stable supply and achieve a smooth transfer of the marketing authorization regarding Xeloda.

Chugai Pharmaceutical Co., Ltd., headquartered in Tokyo, is a research-based pharmaceutical company with world-class drug discovery capabilities, including proprietary antibody engineering technologies. Chugai is committed to creating innovative pharmaceutical products that may satisfy unmet medical needs.

Cheplapharm is a pharmaceutical company established in April 2023 as a Japanese subsidiary of Cheplapharm Arzneimittel GmbH, headquartered in Germany, and began operations in November 2023. The company takes over well-known and well-established medicines from the research-based pharmaceutical industry and transferring them to an existing global network of partners for production and distribution.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!